(864) 370-3297 info@glytecsystems.com

Solutions
About
Resources
Get a Demo

Insulin Management and COVID-19 Resources

What We Know About Patients with Diabetes and COVID-19

Why Glycemic Control is Important:

It has been widely studied that the incidence of diabetes predisposes patients to an increased risk of infections¹ and an increased risk of complications during infection². Additionally, the occurrence of hyperglycemia contributes to an impaired immune response.³

Emerging Studies on COVID-19 and Diabetes Suggest:

Patients with diabetes appear to be at risk for worse outcomes with COVID-19.
Patients with diabetes have an increase in mortality when infected with COVID-19^4,6-10
There is a greater incidence in patients with diabetes in the intensive care unit (ICU) compared to those without the preexisting condition^8,10
Physiological factors, such as the increased expression of ACE-2 receptors in patients with diabetes, may potentially increase the susceptibility of patients to COVID-19 infection⁷

Focus on Basic Glycemic Management Best Practices

Standard Recommendations for Patients That Need Insulin Therapy:

Insulin should be used for the majority of hospitalized patients with hyperglycemia
Continuous intravenous insulin infusion should be utilized to treat persistent hyperglycemia for critically ill patients
Intravenous insulin infusions should be administered based on validated written or computerized protocols that allow for predefined adjustments in the infusion rate, account for glycemic fluctuations and achieve low rates of hypoglycemia
Use of only a sliding scale insulin regimen in the inpatient hospital setting is strongly discouraged
A basal insulin or a basal plus bolus correction insulin regimen with mealtime adjustments as warranted is preferred to treat noncritically ill hospitalized patients
Transition patients to subcutaneous insulin schedules using institutional protocols before discontinuing intravenous insulin infusions

How Glytec Can Help

Existing Glytec Customers:

If you need to create new ICUs or ICU beds, we are providing no-fee expansions and a dedicated support team to expedite Glucommander configurations for these beds.

If you have a support issue that requires immediate assistance, please call our 24/7 help desk at 888-458-2683. For all other support-related matters, please send an email message to support@glytecsystems.com (do not include protected health information or other sensitive data).

Contact Us

Have a question? Need more information? We are here for you. Click here to fill out a form and a Glytec representative will respond within the next business day.

Additional Resources

Diabetes Resources

Joslin
ISPAD
JDRF
ADA
AACE
SANSUM

COVID-19 Provider Resources

SHM Resources
ACP Resources, and Annals IM
SCCM Resources
CDC COVID-19
CDC Publications
Interactive Johns Hopkins coronavirus map
WHO Situation Reports
SCCM online resources for the Non-ICU Clinician
Pubmed’s LitCovid with information specific to diabetes
WHO’s COVID19 research database

Citations

Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41:281–8.
Miller AC, Subranian RA, Safi F, Sinert R, Zehtabchi S, Elamin EM. Influenza A 2009 (H1N1) virus in admitted and critically ill patients. J Intensive Care Med. 2011;27:25–31
Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM) FEMS Immunol Med Microbiol. 1999;26:256–65.
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. Published online February 24, 2020. doi:10.1001/jama.2020.2648.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China [published online ahead of print, 2020 Mar 3]. Intensive Care Med. 2020;1–3. doi:10.1007/s00134-020-05991-.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3)
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? [published online ahead of print, 2020 Mar 11]. Lancet Respir Med. 2020;S2213-2600(20)30116-8. doi:10.1016/S2213-2600(20)30116-8)
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30;:]. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. Published online March 23, 2020. doi:10.1001/jama.2020.4683
Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China [published online ahead of print, 2020 Feb 28]. N Engl J Med. 2020;0:NEJMoa2002032. doi:10.1056/NEJMoa2002032
American Association of Clinical Endocrinologists. AACE.com. https://www.aace.com/disease-state-resources/diabetes/depth-information/management-hyperglycemia-critical-care-setting. Accessed April 9, 2020.
Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2020. American Diabetes Association Diabetes Care Jan 2020, 43 (Supplement 1) S193-S202; DOI:2337/dc20-S015
Jacobi et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Critical Care Medicine: December 2012 - Volume 40 - Issue 12 - p 3251-3276 doi: 10.1097/CCM.0b013e3182653269
Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):775–787. doi:10.1001/jama.2016.0289
Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017;45(3):486–552. doi:10.1097/CCM.0000000000002255
Gosmanov AR, Gosmanova EO, Dillard-Cannon E. Management of adult diabetic ketoacidosis. Diabetes Metab Syndr Obes. 2014;7:255–264. Published 2014 Jun 30. doi:10.2147/DMSO.S50516
Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. 2009. Hyperglycemic crises in adult patients with diabetes. Diabetes Care, 32(7): 1335‐
Ullal J, Aloi JA, Reyes-Umpierrez D, et al. Comparison of Computer-Guided Versus Standard Insulin Infusion Regimens in Patients With Diabetic Ketoacidosis. J Diabetes Sci Technol 2018; 12(1): 39-46. [http://dx.doi.org/10.1177/1932296817750899] [PMID: 29291648]
Lazar et al. The Society of Thoracic Surgeons practice guideline series: Blood glucose management during adult cardiac surgery.Ann Thorac Surg. 2009 Feb;87(2):663-9. doi: 10.1016/j.athoracsur.2008.11.011.
Ian Blumer, Eran Hadar, David R. Hadden, Lois Jovanovič, Jorge H. Mestman, M. Hassan Murad, Yariv Yogev, Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 98, Issue 11, 1 November 2013, Pages 4227–4249, https://doi.org/10.1210/jc.2013-2465
Aloi J, Bode BW, Ullal J, et al. Comparison of an electronic glycemic management system versus provider-managed subcutaneous basal bolus insulin therapy in the hospital setting. J Diabetes Sci Technol 2017; 11(1): 12-6. [http://dx.doi.org/10.1177/1932296816664746] [PMID: 27555601]
Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, et al. 2012. Management of hyperglycemia in hospitalized patients in non‐critical care setting: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 97(1);16‐
Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care. 2004;27(8):1873–1878. doi:10.2337/diacare.27.8.1873

Subscribe to our blog

About Glytec 
Glytec is the insulin management software company for healthcare systems focused on improving the quality and cost of care. Its FDA-cleared titration software, proprietary algorithms, and innovative analytics tools like GlucoMetrics® power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its nationwide team of clinicians, health system leaders, and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes.

Terms of Use
Legal Disclaimer
Privacy Policy
Contraindications, Warnings and Precautions

© 2024 Glytec, LLC

The eGlycemic Management System^® is a modularized solution for glycemic management across the care continuum that includes Glucommander^®. Glucommander^® is a prescription-only software medical device for glycemic management intended to evaluate current as well as cumulative patient blood glucose values coupled with patient information including age, weight and height, and, based on the aggregate of these measurement parameters, whether one or many, recommend an IV dosage of insulin, glucose or saline or a subcutaneous basal and bolus insulin dosing recommendation to adjust and maintain the blood glucose level towards a configurable physician- determined target range. Glucommander^® is indicated for use in adult and pediatric (ages 2-17 years) patients. The measurements and calculations generated are intended to be used by qualified and trained medical personnel in evaluating patient conditions in conjunction with clinical history, symptoms, and other diagnostic measurements, as well as the medical professional’s clinical judgement. No medical decision should be based solely on the recommended guidance provided by this software program.

Glucommander^® is only available for use in the United States.

This site is only intended for use in the United States.